Block, Valerie J. http://orcid.org/0000-0001-6199-5484
Pitsch, Erica A.
Gopal, Arpita
Zhao, Chao
Pletcher, Mark J.
Marcus, Gregory M.
Olgin, Jeffrey E.
Hollenbach, Jill
Bove, Riley
Cree, Bruce A. C.
Gelfand, Jeffrey M.
Funding for this research was provided by:
National Center for Advancing Translational Sciences (KL2TR000143)
Article History
Received: 26 April 2021
Revised: 27 July 2021
Accepted: 3 August 2021
First Online: 17 August 2021
Declarations
:
: Drs. Block, Pitsch, Gopal, Pletcher, Marcus, Olgin and Hollenbach has no relevant disclosures. Mr. Zhao has no relevant disclosures. Dr. Bove is a National Multiple Sclerosis Society Harry Weaver Scholar. She has received research support from the NMSS, CIAPM, Hilton Foundation, Sherak Foundation, Akili Therapeutics, Biogen and Roche Genentech. She has received personal consulting and advisory board fees from Alexion, Biogen, EMD-Serono, Genzyme-Sanofi, Momenta, Novartis, and Roche-Genentech. Dr. Cree has received personal compensation for consulting from Alexion, Atara, Biogen, EMD Serono, Novartis, Sanofi and TG Therapeutics. Dr. Gelfand received research support to UCSF from Genentech. Consulting for Biogen and Alexion.
: The UCSF Institutional Review Board (Ethics Committee) approved the study protocol. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
: All participants provided written informed consent electronically.